文献速递糖尿病

吸入胰岛素联合基础胰岛素与常规治疗在成人1型糖尿病中的随机对照试验

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

在19个中心,成人1型糖尿病患者随机分为吸入Technosphere胰岛素(TI)联合德谷胰岛素组(N=62)或常规治疗组(N=61,继续原胰岛素输注方式),治疗17周。结果显示TI组HbA1c非劣于常规治疗组(调整差值0.11%,95%CI -0.10至0.33,非劣效性P=0.01)。TI常见副作用为短暂咳嗽,8例因副作用停用。

要点

  • TI联合德谷胰岛素治疗17周后HbA1c非劣于常规治疗(主要为AID或MDI)。
  • TI组HbA1c改善>0.5%者12例(21%),常规治疗组3例(5%)。
  • TI组HbA1c恶化>0.5%者15例(26%),常规治疗组2例(3%)。

核心结论

  • 在成人1型糖尿病患者中,TI联合德谷胰岛素治疗17周后HbA1c非劣于常规治疗(主要为AID或MDI)。
  • 作者认为TI应被视为1型糖尿病患者的一种选择,尤其是那些有意愿进一步降低餐后高血糖者。

研究设计与样本

  • 在19个中心进行的随机对照试验,成人1型糖尿病患者随机分为TI联合德谷胰岛素组(N=62)或常规治疗组(N=61,继续原胰岛素输注方式),治疗17周。
  • 研究前使用AID者占48%,使用MDI者占45%。

主要发现

  • TI组基线HbA1c均值±SD为7.57%±0.97%,17周时为7.62%±1.06%;常规治疗组分别为7.59%±0.80%和7.54%±0.77%;调整差值0.11%,95%CI -0.10至0.33,非劣效性P=0.01。
  • TI组HbA1c从基线至17周改善>0.5%(5.5 mmol/mol)者12例(21%),常规治疗组3例(5%)。
  • TI组HbA1c恶化>0.5%(5.5 mmol/mol)者15例(26%),常规治疗组2例(3%)。
  • TI最常见副作用为短暂咳嗽;8例参与者因副作用停用TI。

临床怎么用

  • 作者认为TI应被视为1型糖尿病患者的一种选择,尤其是那些有意愿进一步降低餐后高血糖者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring. RESEARCH DESIGN AND METHODS: At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks. RESULTS: Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI -0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects. CONCLUSIONS: In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hirsch IB, Beck RW, Marak MC, et al. A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Diabetes Care. 2025. PMID: 39641970. doi:10.2337/dc24-1832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。